Disclosed in the present invention is an application of conjugated bilirubin as a biomarker in preparation of a diagnosis device for evaluating a risk of neonatal biliary atresia. Also disclosed in the present invention are a bilirubin content measurement method, a stable quantitative detection reagent for bilirubin, and an application of the quantitative detection reagent for bilirubin in preparation of a kit for measuring a content of the bilirubin and evaluating a risk of biliary atresia of a subject, infant hepatitis syndrome, ?1 antitrypsin deficiency disease or Alagille syndrome. Also disclosed in the present invention are a kit for measuring the content of the bilirubin or evaluating the risk of neonatal biliary atresia, an application of the kit, a method for evaluating the risk of neonatal biliary atresia, and a device for predicting the risk of neonatal biliary atresia by using an expression level of the conjugated bilirubin. The present invention has the advantages of being simple and rapid, flexible in sample preparation, low in limit of detection, good in repeatability and high in sensitivity; and the sample preparation and detection method is simple and easy to implement, low in cost and suitable for popularization and use.

The invention relates to a topical composition containing a bilirubin-producing plant extract. In particular, the bilirubin-producing plant extract is obtained from the genus Stelitzia. When topically applied to skin, the composition is effective in accelerating the degradation of heme by-products such as bilirubin present in the skin.

The present invention discloses a diagnostic device or kit for visual detection of bilirubin. Said diagnostic device or kit comprises chitosan stabilized gold nanoclusters based luminescence source, Cu.sup.2+ ions source for quenching luminescence intensity of said gold nanoclusters and recovery of quenched luminescence intensity in the presence of bilirubin. The said device enables non-invasive detection of hyper-bilirubinemia by thumb impression visually or from blood serum.

The present invention provides a method of measuring a component in blood, by which an amount of the component can be corrected accurately by measuring a hematocrit (Hct) value of the blood with high accuracy and high reliability and also provides a sensor used in the method. The method of measuring a component in blood using a biosensor comprising a first electrode system including a first working electrode on which at least an oxidoreductase that acts upon the component and a mediator are provided and a first counter electrode and a second working electrode on which the mediator is not provided. The first working electrode and the first counter electrode are used for obtaining the amount of the component and the second working electrode and the first working electrode are used for obtaining the amount of the blood cells.

Fluorescent proteins (Chlopsid FP I from Kaupichthys hyoproroides and Chlopsid FP II from Kaupichthys n. sp.) are used in a method for detecting bilirubin. The proteins are based on transcriptome analysis of the false moray eels, Kaupichthys hyoproroides and Kaupichthys n. sp., the later representing a heretofore undescribed species.

The present invention relates to treatment of subgroups of cancer patients, methods for identifying treatment and dosage regimens, as well as methods for identifying these subgroups of cancer patients.

A Quality Control (QC) material for performing a QC procedure with respect to at least one detector is introduced. The QC material comprises at least one first QC substance and at least one second QC substance, wherein the first QC substance is interferable with the second QC substance or with the performance and/or lifetime of the detector and wherein the first QC substance is entrapped by carrier particles that prevent the first QC substance to interfere with the second QC substance or with the performance and/or lifetime of the detector. An in-vitro diagnostic system comprising a first detector and a second detector and the QC material is also introduced. An in-vitro diagnostic method comprising performing a QC procedure with respect to a first detector and/or to a second detector comprising providing the QC material is also introduced, as well as a method of manufacturing the QC material.

Provided is a measurement method whereby the amount of unbound bilirubin (UB) can be exactly reflected whether a specimen contains a large amount of conjugated bilirubin or not. The measurement method for UB according to the present invention comprises decomposition step (i), decomposition stopping step (ii), contact step (iii) and detection step (iv). In decomposition step (i), a blood sample containing unconjugated bilirubin (iD-Bil) and conjugated bilirubin (D-Bil) is subjected to an oxidative decomposition reaction of UB in iD-Bil and D-Bil. In decomposition stopping step (ii), the oxidative decomposition reaction is stopped to give a decomposition product of the sample. In contact step (iii), the decomposition product of the sample is contacted with UnaG that is capable of specifically binding to iD-Bil. Separately, an unreacted sample, which is the blood sample not subjected to decomposition step (i), is contacted with UnaG too. In detection step (iv), the fluorescence of UnaG is detected from the decomposition product of the sample and from the unreacted sample. Then, the amount of UB is derived from the difference between the detected values.

The present invention provide water soluble polyfluorenes functionalized with glucuronic acid useful in sensing bilirubin in aqueous medium and process for preparation thereof. The invention further deals with detecting bilirubin in human serum samples in the range from normal (<25 mol/L1.2 mg/dL) human bilirubin level to jaundiced bilirubin level (>50 mol/L2.5 mg/dL)..sup.1 This is a fluorescence turn-off mode of detection where blue fluorescence of polymer quenches and becomes colorless. The water soluble polyfluorenes functionalized with glucuronic acid can detect free bilirubin in the range from 110.sup.4 M to 110.sup.7 M moles in aqueous and buffer media as a change in the fluorescence signal.

The present invention provides a method of measuring a component in blood, by which an amount of the component can be corrected accurately by measuring a hematocrit (Hct) value of the blood with high accuracy and high reliability and also provides a sensor used in the method. The method of measuring a component in blood using a biosensor comprising a first electrode system including a first working electrode on which at least an oxidoreductase that acts upon the component and a mediator are provided and a first counter electrode and a second working electrode on which the mediator is not provided. The first working electrode and the first counter electrode are used for obtaining the amount of the component and the second working electrode and the first working electrode are used for obtaining the amount of the blood cells.